Stockscreener 앱 받기
4.15
2.76%
-0.10
Exagen Inc 주식(XGN)의 최신 뉴스
ETFs Investing in Exagen, Inc. Stocks - TradingView
Exagen Inc focuses on autoimmune diagnostics as investors watch strategy - Ad Hoc News
Exagen Company Profile & Introduction - Moomoo
XGNExagen Inc Volatility & Greeks - Finviz
Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support LevelNAAIM Leverage - dars.gov.et
Price to earnings forward of Exagen, Inc. – LS:A2PRXT - TradingView
Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN - TradingView
A2PRXT Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
XGN Q1 2026 Earnings: EPS Beat Drives Positive Stock MovementStrong Earnings Momentum - dars.gov.et
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Exagen StockSunday background on autoimmune diagnostics specialist - AD HOC NEWS
Exagen advances use of new RA biomarkers to refine patient risk assessment - Traders Union
Exagen Inc (XGN) Institutional Confidence - TradingKey
XGN Q1 2026 Earnings: EPS Surprises with 15.15% Beat; Stock Gains 6.82%EPS Consistency Score - dars.gov.et
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets - Yahoo Finance
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
0.69%
1.90%
자본화:
|
볼륨(24시간):